AVXL vs. SOPH, IVVD, CRBU, JSPR, GLUE, MGTX, PSTX, CADL, ADAP, and TNYA
Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include SOPHiA GENETICS (SOPH), Invivyd (IVVD), Caribou Biosciences (CRBU), Jasper Therapeutics (JSPR), Monte Rosa Therapeutics (GLUE), MeiraGTx (MGTX), Poseida Therapeutics (PSTX), Candel Therapeutics (CADL), Adaptimmune Therapeutics (ADAP), and Tenaya Therapeutics (TNYA). These companies are all part of the "biological products, except diagnostic" industry.
Anavex Life Sciences (NASDAQ:AVXL) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation.
Anavex Life Sciences has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
Anavex Life Sciences has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -126.63%. Anavex Life Sciences' return on equity of -30.32% beat SOPHiA GENETICS's return on equity.
Anavex Life Sciences received 407 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. Likewise, 74.08% of users gave Anavex Life Sciences an outperform vote while only 72.73% of users gave SOPHiA GENETICS an outperform vote.
Anavex Life Sciences has higher earnings, but lower revenue than SOPHiA GENETICS. Anavex Life Sciences is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks.
In the previous week, Anavex Life Sciences had 7 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 15 mentions for Anavex Life Sciences and 8 mentions for SOPHiA GENETICS. SOPHiA GENETICS's average media sentiment score of 0.31 beat Anavex Life Sciences' score of 0.03 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.
Anavex Life Sciences presently has a consensus price target of $40.00, suggesting a potential upside of 978.17%. SOPHiA GENETICS has a consensus price target of $8.00, suggesting a potential upside of 73.91%. Given Anavex Life Sciences' higher possible upside, equities analysts plainly believe Anavex Life Sciences is more favorable than SOPHiA GENETICS.
31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 11.6% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Anavex Life Sciences beats SOPHiA GENETICS on 10 of the 16 factors compared between the two stocks.
Get Anavex Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anavex Life Sciences Competitors List
Related Companies and Tools
